Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical update reported in June 2026 and provide the first broader safety and efficacy assessment of VS-7375 across these tumor types. VS-7375 is a potential best-in-class, potent and selective investigational oral KRAS G12D (ON/OFF) inhibitor.

Verastem’s management team will be joined by Manuel Hidalgo Medina, M.D., Ph.D., a leading medical oncologist who serves as director of the Gastrointestinal Cancer Center at New York University (NYU) Langone Health and as a professor of medicine at NYU Grossman School of Medicine. Dr. Hidalgo is an investigator in the ongoing Phase 1 and Phase 2 trials evaluating VS-7375. Dr. Hidalgo has over two decades of experience in translational and clinical research in anti-cancer drug development with an emphasis on pancreatic cancer.